Press release
The Rise In The Prevalence Of RSV Infection : Transformative Forces Shaping the Respiratory Syncytial Virus (RSV) Therapeutics Market Landscape in 2025
Respiratory Syncytial Virus (RSV) Therapeutics Market
What Will the Respiratory Syncytial Virus (RSV) Therapeutics Industry Market Size Be by 2025?
The market size for therapeutics treating the respiratory syncytial virus (RSV) has seen significant expansion in the past few years. It is expected to surge from $1.6 billion in 2024 to $2 billion in 2025, maintaining an impressive compound annual growth rate (CAGR) of 25.0%. Factors contributing to this historic growth trend include heightened awareness of the disease, breakthroughs in virology, the susceptibility of children, epidemic occurrences, and vaccine advancements.
What's the Long-Term Growth Forecast for the Respiratory Syncytial Virus (RSV) Therapeutics Market Size Through 2029?
The market size of therapeutics for the respiratory syncytial virus (RSV) is projected to see a significant surge in the upcoming years, reaching $4.59 billion in 2029 with a compound annual growth rate (CAGR) of 23.1%. The predicted expansion during the forecast period is linked to factors such as the innovation in biologic therapies, the rise of new antivirals, increased attention to the aging population, strategies for maternal immunization, and worldwide research partnerships. Key trends for this period involve advancements in monoclonal antibodies, development in nasal vaccines and their delivery methods, combination treatments, novel techniques in drug delivery, and options for treatment at home.
View the full report here:
https://www.thebusinessresearchcompany.com/report/respiratory-syncytial-virus-rsv-therapeutics-global-market-report
What Are the Key Growth Drivers Fueling the Respiratory Syncytial Virus (RSV) Therapeutics Market Expansion?
The surge in RSV infection cases is a key contributor to the expansion of the respiratory syncytial virus (RSV) therapeutics market. RSV is a common respiratory ailment that can trigger mild to serious respiratory infections, predominantly in newborns, young children, elderly individuals, and those with weakened immune systems. The rising occurrences of RSV infections necessitate the creation of novel treatments to fulfill the increasing demand and alleviate the intensity of RSV-linked complications. For example, in September 2023, the Centres for Disease Control and Prevention, a public health agency based in the U.S., reported a substantial hike in RSV-related hospitalization rates among children under 4 years. The figures rose from 2.0 hospitalizations per 100,000 population for the week ending August 5, 2023, to 7.0 hospitalizations per 100,000 population by August 19, 2023. Therefore, the escalating prevalence of RSV infection fuels the growth of the respiratory syncytial virus (RSV) therapeutics market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12601&type=smp
What Are the Key Trends Driving Respiratory Syncytial Virus (RSV) Therapeutics Market Growth?
The trend of inventing new and more effective drugs and vaccines is burgeoning in the Respiratory Syncytial Virus (RSV) therapeutics market. The prominent corporations in the market are putting their efforts into innovating fresh drugs and vaccines to secure their stakes in the market. For example, Pfizer Inc., an American pharmaceutical manufacturing company, was granted clearance for ABRYSVO by the Food and Drug Administration, a US federal body entrusted with the safety and promotion of public health, in May 2023. The dual component RSVprefusion F (RSVpreF) vaccine ABRYSVO (Respiratory Syncytial Virus Vaccine) is administered to prevent the lower respiratory tract diseases caused by RSV in people aged 60 or above. ABRYSVO, an unadjuvanted vaccine formulated of a pair of preF proteins that are custom-made to augment immunity against RSV A and B strains, is extensively clinically approved for being safe and effective.
How Is the Respiratory Syncytial Virus (RSV) Therapeutics Market Segmented?
The respiratory syncytial virus (RSV) therapeutics market covered in this report is segmented -
1) By Drug: Palivizumab, Ribavirin, Other Drugs
2) By Treatment: Immune Prophylaxis, Supportive Care, Antiviral Medications
3) By Dosage Form: Oral, Injectable, Other Dosage Forms
4) By Patient Type: Pediatrics, Adults
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Palivizumab: Monoclonal Antibody
2) By Ribavirin: Antiviral Medication
3) By Other Drugs: Cidofovir, Nitazoxanide, Other Experimental Or Off-Label Treatments
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12601&type=smp
Which Companies Are Leading the Charge in Respiratory Syncytial Virus (RSV) Therapeutics Market Innovation?
Major companies operating in the respiratory syncytial virus (RSV) therapeutics market include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc., Gilead Sciences Inc., Moderna Inc., Regeneron Pharmaceuticals Inc., Novavax AB, Vir Biotechnology Inc., Lupin Limited, Kyorin Pharmaceutical Co. Ltd., Bavarian Nordic A/S, SciClone Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Hetero Healthcare Ltd, Inovio Pharmaceuticals Inc., Ascletis Pharma Inc., NanoBio Corporation, Vaxart Inc., Ark Biosciences Private Limited, Pulmocide Ltd
Which Regions Are Leading the Global Respiratory Syncytial Virus (RSV) Therapeutics Market in Revenue?
North America was the largest region in the respiratory syncytial virus (RSV) therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus (RSV) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12601
This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The Rise In The Prevalence Of RSV Infection : Transformative Forces Shaping the Respiratory Syncytial Virus (RSV) Therapeutics Market Landscape in 2025 here
News-ID: 4100359 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for RSV
The Rise In The Prevalence Of RSV Infection : A Key Catalyst Accelerating Global …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Respiratory Syncytial Virus (RSV) Therapeutics Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market encompassing therapeutics for respiratory syncytial virus (rsv) has witnessed substantial, rapid expansion lately, projected to increase its valuation from $1.6 billion in 2024 to $2 billion just one year later…
RSV Vaccine Market To Reach 731 million by 2040, Due To Increasing Awareness on …
According to our latest market report "RSV Vaccine Market, Till 2040 by Type of Vaccine, Route of Administration, Target Patient Population, Distribution Channel, Key Geographical Regions and Leading Players", the RSV Vaccine market size is projected to reach USD 731 million by 2040 from USD 1,149 million in current year, during the forecast period.
To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/rsv-vaccine-market/request-quote.html
In the dynamic landscape of preventive therapies for respiratory…
Global RSV Diagnostic Products Market Size & Trends
According to a new market research report published by Global Market Estimates, the global RSV diagnostic products market is expected to grow at a CAGR of 11.4% from 2023 to 2028.
Ongoing advancements in diagnostic technologies, specifically PCR and rapid point-of-care testing, play a crucial role. These advancements offer heightened accuracy, faster results, and increased accessibility, enabling prompt and precise identification of RSV infections.
Browse 147 Market Data Tables and 115 Figures…
Respiratory Syncytial Virus (RSV) Therapeutics Market Size to Reach USD 9080.84 …
Respiratory Syncytial Virus (RSV) Therapeutics Market Scope & Overview
Respiratory Syncytial Virus (RSV) Therapeutics Market size was USD 1040.65 Million in 2022 and is expected to Reach USD 9080.84 Million by 2030 and grow at a CAGR of 31.1% over the forecast period of 2023-2030.
The Respiratory Syncytial Virus (RSV) Therapeutics market is a vibrant, fiercely competitive sector that is essential to digital marketing. The demand for effective has increased as companies…
Respiratory Syncytial Virus (RSV) Therapeutics Market - Conquering RSV: Advancin …
Newark, New Castle, USA: The "Respiratory Syncytial Virus (RSV) Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Respiratory Syncytial Virus (RSV) Therapeutics Market: https://www.growthplusreports.com/report/respiratory-syncytial-virus-rsv-therapeutics-market/8519
This latest report…
Synagis (Pediatric RSV) - Forecast And Market Analysis To 2022
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, Synagis (Pediatric RSV) Forecast and Market Analysis to 2022. Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread through the air by an infected persons sneeze or…
